Skip to search formSkip to main contentSkip to account menu

Folinic Acid-Fluorouracil-Irinotecan Regimen

Known as: FOLFIRI, FOLFIRI regimen 
An abbreviation for a chemotherapy combination used to treat advanced colorectal cancer that has spread. It is also being studied in the treatment of… 
National Institutes of Health

Related topics

Related topics

6 relations
Colorectal CarcinomaFluorouracilIFL protocolIrinotecan hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance…
3504Background: 80405 found no OS or PFS difference when Bevacizumab (BV) or Cetuximab (Cet) was added to 1st-line FOLFOX or… 
Highly Cited
2015
Highly Cited
2015
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Data on gastroenteropancreatic neuroendocrine neoplasms (NEN) G3 (well-differentiated neuroendocrine tumors (NET G3) and… 
Highly Cited
2014
Highly Cited
2014
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt…
LBA3 Background: Irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6), combined with bevacizumab (BV… 
Highly Cited
2014
Highly Cited
2014
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
BACKGROUND Initially, unresectable colorectal liver metastases can be resected after response to chemotherapy. While cetuximab… 
Highly Cited
2012
Highly Cited
2012
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
PURPOSE Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has demonstrated… 
Highly Cited
2010
Highly Cited
2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Highly Cited
2007
Highly Cited
2007
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
BACKGROUND The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a… 
Highly Cited
2007
Highly Cited
2007
Survival After Radiofrequency Ablation of Colorectal Liver Metastases: 10-Year Experience
Objective:To assess factors affecting long-term survival of patients undergoing radiofrequency ablation (RFA) of colorectal… 
Highly Cited
2007
Highly Cited
2007
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
PURPOSE In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of… 
Highly Cited
1999
Highly Cited
1999
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)